GlassScriptPhysician profile
Robert J Karman
NPI 1588695886
$3,401.75
in general payments reported to CMS, 2019-2025
21 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $156 · 2021: $151 · 2022: $670 · 2023: $768 · 2024: $580 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.19 |
| Education | $112.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $888.37 | 2019-2025 | |
| Inspire Medical Systems, INC. | $790.52 | 2019-2025 | Inspire |
| Axsome Therapeutics, INC. | $440.51 | 2023-2025 | Sunosi, Auvelity |
| Harmony Biosciences LLC | $364.70 | 2022-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $220.10 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $167.30 | 2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $111.74 | 2023-2024 | Austedo Xr |
| Fisher & Paykel Healthcare INC | $96.80 | 2023-2025 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $94.00 | 2020-2023 | Belsomra |
| Amgen INC. | $26.47 | 2023-2024 | Repatha, Otezla |
| Aprecia Pharmaceuticals, LLC | $26.19 | 2023 | Spritam |
| Acadia Pharmaceuticals INC | $25.36 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.90 | 2025 | Belbuca |
| Tersera Therapeutics LLC | $19.79 | 2025 | Prialt |
| Sk Life Science, INC. | $18.02 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $17.83 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $16.23 | 2025 | Lumryz |
| Eisai INC. | $16.11 | 2021 | |
| Resmed Corp | $14.74 | 2022 | |
| Abbvie INC. | $13.75 | 2023 | |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Karman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.